Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$4.07 USD
+0.14 (3.56%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.02 -0.05 (-1.23%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Earnings News For AQST
-
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
-
Aquestive Therapeutics: Q4 Earnings Snapshot
-
Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect
-
Aquestive Therapeutics: Q3 Earnings Snapshot
-
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
-
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
-
Aquestive Therapeutics: Q2 Earnings Snapshot
-
Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
-
Aquestive (AQST) to Report Q2 Earnings: What's in Store?
-
Aquestive Therapeutics (AQST) Tops Q1 Earnings and Revenue Estimates
-
Aquestive Therapeutics: Q1 Earnings Snapshot
-
Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
-
Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
-
Aquestive Therapeutics: Q4 Earnings Snapshot
-
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
-
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
-
Aquestive Therapeutics (AQST) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
-
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
-
Aquestive Therapeutics: Q3 Earnings Snapshot
-
Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
-
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
-
Aquestive Therapeutics: Q2 Earnings Snapshot
-
Aquestive Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates
-
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates